Investigational drug · Phase 3
Ralinepag
Also called: APD811
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for PAH, Pulmonary Hypertension, Pulmonary Arterial Hypertension.
Phase 3Last checked: Nov 19, 2026Latest source record: Oct 6, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
6
Any phase or sponsor naming "Ralinepag"
First trial start
2019
Jan 24, 2019
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "Ralinepag", any sponsor or status.
Conditions studied
As listed on its trial records.
- PAH
- Pulmonary Hypertension
- Pulmonary Arterial Hypertension
- Hypertension
- Connective Tissue Diseases
- Familial Primary Pulmonary Hypertension
- Vascular Diseases
- Cardiovascular Diseases
- Hypertension, Pulmonary
- Lung Diseases
Approved drugs for the same conditions: High blood pressure (hypertension) · Pulmonary arterial hypertension · Cardiovascular and metabolic · Respiratory
Largest trials
Live from ClinicalTrials.gov: studies naming "Ralinepag" as an intervention, largest first.
- A Study Evaluating the Long-Term Efficacy and Safety of Ralinepag in Subjects With PAH Via an Open-Label ExtensionPivotal-lookingEnrolling by invitation
United TherapeuticsIndustry
NCT03683186 · 1,000 participants (planned) · Start Sep 23, 2019 · Primary completion Dec 2026
Drug: Ralinepag · For: PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension and 8 more
Sites: Phoenix, Arizona; Tucson, Arizona; La Jolla, California · 190 sites in all
- A Study Evaluating the Efficacy and Safety of Ralinepag to Improve Treatment Outcomes in PAH PatientsPivotal-lookingCompleted
United TherapeuticsIndustry
NCT03626688 · 687 participants · Start Jan 24, 2019 · Primary completion Dec 31, 2025
Drug: Ralinepag; Placebo · For: PAH; Pulmonary Hypertension; Pulmonary Arterial Hypertension and 8 more
Sites: Birmingham, Alabama; Phoenix, Arizona; Tucson, Arizona · 209 sites in all
United TherapeuticsIndustry
NCT02279160 · 61 participants · Start Dec 2014 · Primary completion Jun 2017
Drug: APD811; Placebo · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Los Angeles, California; Sacramento, California · 35 sites in all
United TherapeuticsIndustry
NCT02279745 · 45 participants · Start Jul 8, 2015 · Primary completion Mar 29, 2021
Drug: Ralinepag · For: Pulmonary Arterial Hypertension
Sites: Birmingham, Alabama; Beverly Hills, California; Los Angeles, California · 46 sites in all
Everstar Medicines (Shanghai) LimitedIndustry
NCT04613999 · 15 participants · Start Oct 9, 2020 · Primary completion Nov 9, 2020
Drug: Ralinepag · For: Healthy Volunteer; Pharmacokinetic Study
Sites: Beijing, China
- Study of Ralinepag on Exercise Capacity by Cardiopulmonary Exercise Testing (CPET) in WHO Group 1 PH SubjectsPivotal-lookingTerminated
United TherapeuticsIndustry
NCT04084678 · 10 participants · Start Jan 20, 2021 · Primary completion Apr 12, 2023
Drug: Ralinepag; Placebo · For: Pulmonary Hypertension; Pulmonary Arterial Hypertension
Sites: Tucson, Arizona; Aurora, Colorado; Denver, Colorado · 33 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Food Effects on the Pharmacokinetics of Single Dose and Steady-State Ralinepag, a Novel Oral Prostacyclin Agonist, in Healthy Volunteers.
Lachant D, Botta CE, Giannakoulas G, et al. · Am J Cardiovasc Drugs 2026
- Ralinepag in pulmonary arterial hypertension: a step forward.
Balasubramanian A, Mathai SC · Lancet 2026
- Ralinepag for the treatment of pulmonary arterial hypertension (ADVANCE OUTCOMES): a randomised, double-blind, placebo-controlled phase 3 study.
McLaughlin VV, Solum D, Lachant D, et al. · Lancet 2026
- Safety and pharmacokinetics of ralinepag, a novel oral prostacyclin receptor agonist.
Ataya A, Coons JC, Patzlaff N, et al. · JHLT Open 2025
- New and Emerging Therapeutic Drugs for the Treatment of Pulmonary Arterial Hypertension: A Systematic Review.
Rasheed A, Aslam S, Sadiq HZ, et al. · Cureus 2024
- "Efficacy and safety of ralinepag, a novel oral IP agonist, in PAH patients on mono or dual background therapy: results from a phase 2 randomised, parallel group, placebo-controlled trial." F. Torres, H. Farber, A. Ristic, et al. Eur Respir J 2019; 54: 1901030.
· Eur Respir J 2024
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.